SCHEMBL4707707

SCHEMBL4707707

CCn1nc(-c2ccccc2)c(C(C)=O)c(Nc2ccc(C(=O)O)cc2C)c1=O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 5/20 0.73
THRB P10828 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
TP53 P04637 1/20 0.41
PTGFR P43088 1/20 0.41
PDE4A P27815 3/20 0.41
PDE4C Q08493 3/20 0.41
PDE4D Q08499 3/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
CSF1R P07333 1/20 0.39
FGFR1 P11362 1/20 0.39
FLT1 P17948 1/20 0.39
KDR P35968 1/20 0.39
CSNK1A1 P48729 1/20 0.39
CDK8 P49336 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
CDK5 Q00535 1/20 0.39
PRKCQ Q04759 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3042771 0.91 PDE4B (0.61) PDE4BTHRB
SCHEMBL4707900 0.90 PDE4B (0.73) PDE4BSMN1; SMN2TP53PTGFRPDE4A
SCHEMBL4894028 0.89 PDE4B (0.72) PDE4BSMN1; SMN2TP53PTGFR
SCHEMBL4707452 0.89 PDE4B (0.72) PDE4BSMN1; SMN2TP53PTGFRCSF1R
SCHEMBL4705603 0.88 PDE4B (0.69) PDE4BSMN1; SMN2TP53PDE4APDE4C
SCHEMBL4706593 0.88 PDE4B (0.69) PDE4BSMN1; SMN2TP53PTGFR
SCHEMBL4889251 0.87 PDE4B (0.72) PDE4BSMN1; SMN2TP53CSF1RFGFR1
SCHEMBL4897616 0.85 PDE4B (0.66) PDE4BSMN1; SMN2TP53PDE4APDE4C
SCHEMBL4708504 0.85 PDE4B (0.65) PDE4BTHRBSMN1; SMN2TP53PDE4A
SCHEMBL4708354 0.85 PDE4B (1.00) PDE4BSMN1; SMN2TP53PDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885THRB 2705/4885SMN1; SMN2 2927/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885THRB 2705/4885SMN1; SMN2 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.